Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities.


Journal

ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411

Informations de publication

Date de publication:
11 Mar 2022
Historique:
received: 31 01 2022
entrez: 21 3 2022
pubmed: 22 3 2022
medline: 22 3 2022
Statut: epublish

Résumé

Schizophrenia is a complex and severe mental illness. Current treatments for schizophrenia typically modulate dopaminergic neurotransmission by D

Identifiants

pubmed: 35311018
doi: 10.1021/acsptsci.2c00016
pmc: PMC8922295
doi:

Types de publication

Journal Article

Langues

eng

Pagination

183-188

Informations de copyright

© 2022 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

N Engl J Med. 2020 Apr 16;382(16):1497-1506
pubmed: 32294346
Mol Pharmacol. 2001 Dec;60(6):1181-8
pubmed: 11723224
ACS Chem Biol. 2009 Mar 20;4(3):209-20
pubmed: 19256523
Schizophr Res. 2018 Apr;194:78-85
pubmed: 28416205
Neuropsychopharmacology. 2017 Mar;42(4):941-950
pubmed: 27857125
Am J Psychiatry. 2012 Nov;169(11):1203-10
pubmed: 23034655
Br J Psychiatry. 2016 Nov;209(5):361-365
pubmed: 27802977
Pharmacol Rev. 2018 Jul;70(3):549-620
pubmed: 29941461
Chem Biol Drug Des. 2013 Apr;81(4):509-16
pubmed: 22883051
Mol Psychiatry. 2020 Sep;25(9):1910-1919
pubmed: 32203158
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Mol Psychiatry. 2021 Aug 10;:
pubmed: 34376825
Pharmacol Ther. 2017 Dec;180:161-180
pubmed: 28723415
N Engl J Med. 2020 Apr 16;382(16):1555-1556
pubmed: 32294351
Eur Neuropsychopharmacol. 2015 Nov;25(11):2049-61
pubmed: 26372541
Neuropsychopharmacology. 2015 Aug;40(9):2217-27
pubmed: 25749299
J Pharmacol Exp Ther. 2019 Oct;371(1):1-14
pubmed: 31371483
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8966-71
pubmed: 11459929
Mol Pharmacol. 2011 Sep;80(3):416-25
pubmed: 21670104

Auteurs

Pramod C Nair (PC)

Discipline of Clinical Pharmacology and Flinders Health and Medical Research Institute (FHMRI), College of Medicine and Public Health, Flinders University, Adelaide, South Australia 5042, Australia.
Discipline of Clinical Pharmacology and Flinders Health and Medical Research Institute (FHMRI), College of Medicine and Public Health, Flinders University, Adelaide, South Australia 5042, Australia.

Justin M Chalker (JM)

Institute for Nanoscale Science and Technology, College of Science and Engineering, Flinders University, Adelaide, South Australia 5042, Australia.

Ross A McKinnon (RA)

Discipline of Clinical Pharmacology and Flinders Health and Medical Research Institute (FHMRI), College of Medicine and Public Health, Flinders University, Adelaide, South Australia 5042, Australia.

Christopher J Langmead (CJ)

Drug Discovery Biology and Neuroscience & Mental Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Drug Discovery Biology and Neuroscience & Mental Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.

Karen J Gregory (KJ)

Drug Discovery Biology and Neuroscience & Mental Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Drug Discovery Biology and Neuroscience & Mental Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.

Tarun Bastiampillai (T)

Department of Psychiatry, Monash University, Clayton, Victoria 3168, Australia.
College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia.

Classifications MeSH